IntelGenx Technologies Corp.
IGX
Rankning i aktier
#28120
IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise... IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise focused on the creation and manufacturing of advanced oral thin film products. The company's diverse product pipeline encompasses various oral film formulations designed to address a wide spectrum of medical conditions. These include INT0008/2008, a Rizatriptan film for migraine management; INT0046/2018 for adult applications; INT0007/2006, an oral film targeting erectile dysfunction; INT0043/2015, a montelukast-based film for Alzheimer's disease; INT0027/2011, intended for opioid addiction treatment; INT0010/2006, addressing neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, formulated for schizophrenia or bipolar I disorder; and INT0048/2020, developed for veterinary health. Additionally, IntelGenx is actively developing other candidates identified as INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has established strategic partnerships, including a comprehensive licensing, development, and supply agreement with Tilray, Inc., alongside a development pact with Cynapsus Therapeutics Inc. Founded in 2003, IntelGenx Technologies Corp. is headquartered in Montreal, Canada.
Aktiekurs
$0.17446996
Senast synkroniserad: 2024-06-11
Marknadsvärde
$26.97M
Förändring (1 dag)
-0.57%
Förändring (1 år)
2.63%
Land
CA
Handel IntelGenx Technologies Corp. (IGX)
Kategori
Healthcare
Vinst för IntelGenx Technologies Corp. (IGX)
Vinst i Mar 2024 TTM: $-11.03M
Enligt de senaste finansiella rapporterna från IntelGenx Technologies Corp. är företagets nuvarande vinst $-11.03M. År 2022 hade företaget en vinst på $-10.69M, en minskning jämfört med vinsten år 2021 som var $-9.32M. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för IntelGenx Technologies Corp. från 2003 till 2026
Vinst vid slutet av varje år
| År | Vinst | Ändra |
|---|---|---|
| 2026 (TTM) | $-11.03M | 11.11% |
| 2023 | $-9.93M | -7.14% |
| 2022 | $-10.69M | 14.72% |
| 2021 | $-9.32M | 32.28% |
| 2020 | $-7.04M | -33.92% |
| 2019 | $-10.66M | 5.46% |
| 2018 | $-10.11M | 231.30% |
| 2017 | $-3.05M | 158.56% |
| 2016 | $-1.18M | -191.40% |
| 2015 | $1.29M | -173.94% |
| 2014 | $-1.75M | 6.53% |
| 2013 | $-1.64M | -27.16% |
| 2012 | $-2.25M | -8.24% |
| 2011 | $-2.45M | -20.80% |
| 2010 | $-3.10M | 49.51% |
| 2009 | $-2.07M | -30.00% |
| 2008 | $-2.96M | 153.92% |
| 2007 | $-1.16M | 49.13% |
| 2006 | $-781.14K | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
Vinst för liknande företag eller konkurrenter
| Företag | Vinst | Skillnad i vinst | Land |
|---|---|---|---|
| $5.27B | -47,923.21% |
US
|
|
| $-3.09B | 27,887.31% |
US
|
|
| $-4.02B | 36,311.57% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -17,784.95% |
NL
|
